pravastatin has been researched along with methylprednisolone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ando, T; Arisaka, O; Hoshi, E; Ito, S; Kano, K; Kyo, K; Tomita, S; Ueda, Y; Yamada, Y | 1 |
| Antikainen, M; Hedman, M; Holmberg, C; Neuvonen, M; Neuvonen, PJ | 1 |
| Asada, A; Iwaki, H; Iwakiri, K; Kaneshiro, Y; Kobayashi, A; Masada, T; Oda, Y; Takaoka, K | 1 |
| Kumagai, K; Miyata, N; Niwa, M; Nozaki, Y | 1 |
| Chang, YW; Cheng, HT; Liao, MT; Lin, WC; Lin, YH; Tsai, IJ; Tsau, YK | 1 |
| Chen, W; Jiang, Y; Li, P; Lin, N; Lu, C; Xu, Y; Zhang, H; Zhang, Y; Zhu, B | 1 |
1 review(s) available for pravastatin and methylprednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for pravastatin and methylprednisolone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Effects of combination therapy consisting of moderate-dose intravenous immunoglobulin G, pulsed methylprednisolone and pravastatin in children with steroid-resistant nephrosis.
Topics: Anticholesteremic Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Infant; Male; Methylprednisolone; Nephrotic Syndrome; Pravastatin | 2000 |
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.
Topics: Administration, Oral; Adolescent; Anticholesteremic Agents; Area Under Curve; Azathioprine; Calcineurin Inhibitors; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Mycophenolic Acid; Pravastatin; Tacrolimus; Triglycerides | 2004 |
Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model.
Topics: Animals; Cytochrome P-450 CYP3A; Female; Glucocorticoids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Liver; Methylprednisolone; Osteonecrosis; Pravastatin; Probucol; Rabbits; Simvastatin | 2008 |
Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats.
Topics: Adipocytes; Animals; Anti-Inflammatory Agents; Bone Marrow; Disease Models, Animal; Drinking Water; Femur Head Necrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipid Metabolism; Male; Methylprednisolone; Methylprednisolone Acetate; Oxidative Stress; Pravastatin; Rats; Rats, Inbred SHR | 2012 |
A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy.
Topics: Age of Onset; Anti-Inflammatory Agents; Antihypertensive Agents; Apolipoprotein E2; Child; Enalapril; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Methylprednisolone; Mutation; Nephrotic Syndrome; Pravastatin | 2012 |
Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARγ expression and activating Wnt signaling pathway.
Topics: Adipogenesis; Adipose Tissue; Adrenal Cortex Hormones; Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Femur Head; Femur Head Necrosis; Fibrinolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Low Density Lipoprotein Receptor-Related Protein-5; Male; Methylprednisolone; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; PPAR gamma; Pravastatin; Rats; Rats, Wistar; Wnt Signaling Pathway; Wnt3A Protein | 2014 |